Brazilian FDA calls for contributions on the possibility of allowing skinny labeling in Brazil
On December 28th, the Brazilian Food & Drug Agency (called “Anvisa” in the Portuguese acronym) published a call for comments (#1,137 of 2022) on its proposal to amend its Board of Director’s Rule #47 of 2009, whereby an exemption will be made, allowing generics and branded generics (called also “similar”) to omit patented uses in their labels.